Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care reported robust financial performance for 2021, achieving a 41% increase in sales to $702.8 million. Worldwide pump shipments rose by 41% to 128,312 pumps, with a gross margin of 54%. The company posted a net income of $15.6 million, a turnaround from a $34.4 million loss in 2020. For 2022, Tandem projects sales between $845 million and $860 million, indicating 20% to 22% annual growth. The guidance supports continued investment in innovation and operational improvements.
Tandem Diabetes Care announces FDA clearance for the t:connect mobile app, the first smartphone application allowing bolus insulin delivery via both iOS and Android. This update provides users of the t:slim X2 insulin pump the convenience of programming and canceling bolus requests using their smartphones. Available for free as a software update to existing users, the feature will roll out in limited phases starting in spring. The app enhances diabetes management by displaying glucose trends and pump data securely.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will provide an update at two virtual investor conferences. The first is Citi’s 2022 Virtual Healthcare Conference on February 24, 2022, at 11:00am ET, followed by Cowen's 42nd Annual Health Care Conference on March 9, 2022, at 2:50pm ET. Both presentations will be webcast live, with archives available for 30 days on Tandem's Investor Center website. Tandem is focused on enhancing diabetes care through innovative products like the t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring.
Tandem Diabetes Care (NASDAQ: TNDM) will announce its fourth quarter and full year 2021 results on February 22, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the financial and operational highlights. Interested parties can join the call at (855) 427-4396 (toll-free) or (484) 756-4261 (international). An archived version of the webcast will be available for 30 days on their Investor Center website.
Tandem Diabetes Care announced key management appointments to enhance its leadership team for future growth. Rick Carpenter joins as Chief Technical Officer, bringing over 30 years of engineering experience. Libba Sapitsky becomes Senior Vice President of Customer Care, with extensive background in customer service operations. Rizwan Pervez is appointed Senior Vice President for Quality and Regulatory, having over 20 years in compliance leadership. These roles aim to support product expansion and pipeline execution as Tandem continues its mission to improve diabetes care.
Tandem Diabetes Care (NASDAQ: TNDM) will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 2, 2021. A pre-recorded fireside chat featuring CEO John Sheridan and CFO Leigh Vosseller will be available starting November 22, 2021, at 10:00 AM ET. Investors can access the chat on the Tandem Diabetes Investor Center website under 'Events & Presentations.'
Tandem Diabetes is committed to enhancing diabetes management through innovative solutions, highlighted by its flagship t:slim X2™ insulin pump.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported strong Q3 2021 results, with pump shipments up 43% and sales increasing 45% to $179.6 million. Gross profit rose 48% to $96.7 million, while net income shifted to $5.8 million from a loss in 2020. The company raised its 2021 sales guidance to $685-$695 million, reflecting a growth of 37-39%. International sales soared by 189%, and gross margin improved to 54%. Cash reserves reached $595 million, indicating robust liquidity.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced management will present company updates at two upcoming virtual investor conferences. The first is on November 9, 2021, at 12:10 PM ET during the Credit Suisse 30th Annual Virtual Healthcare Conference, followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 4:00 PM ET. Both presentations will be webcast live, with recordings available for 30 days afterward. Interested parties can access the live and archive webcasts on Tandem's Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will release its third quarter 2021 results on November 3, 2021, after market close. A conference call is scheduled for 4:30 PM ET to discuss the financial and operational outcomes. Interested parties can access the call via toll-free and international dial-in numbers or through a webcast link provided in the release. The event will be archived for 30 days on Tandem's Investor Center website.
Tandem Diabetes Care (NASDAQ: TNDM) has announced upcoming presentations at several virtual investor conferences. These include:
- Wells Fargo 2021 Virtual Health Care Conference on September 9, 2021, at 4:35 PM ET
- Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 3:30 PM ET
- Baird 2021 Global Healthcare Conference on September 15, 2021, at 12:50 PM ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 4:35 PM ET
Live webcasts will be available, with recordings accessible for 30 days on the company’s investor website.
FAQ
What is the current stock price of Tandem Diabetes (TNDM)?
What is the market cap of Tandem Diabetes (TNDM)?
